Comparative aspects of pulmonary toxicity induced by cytotoxic agents with emphasis on lomustine, and a veterinary case report

Vlaams Diergeneeskundig Tijdschrift

Volumn 77, Issue 4, 2008, Pages 248-255

  Van Meervenne, S A E ^a,b   De Vos, J P ^b   Van Ham, L ^c   Bavegems, V ^a  

^a GHENT UNIVERSITY   (Belgium)

^b De Ottenhorst   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 51849099077     PISSN: 03039021     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Abushamaa A.M., Sporn T.A., Folz R.J. (2002). Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. American Journal of Physiology. Lung Cellular and Molecular Physiology 283, L336-L345.
2. Alexandrescu D.T., Karri S., Wiernik P.H., Dutcher J.P. (2006). Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leukemia & Lymphoma 47, 641-656.
3. Block M., Lachowiez R.M., Rios C., Hirschl S. (1990). Pulmonary fibrosis associated with low-dose adjuvant methyl-CCNU. Medical and Pediatric Oncology 18, 256-260.
4. Camus P., Foucher P., Bonniaud P., Ask K. (2001). Drug-induced infiltrative lung disease. European Journal of Respiratory Diseases 18, 93s-100s.
5. Cooper J.A.D., White D.A., Matthay R.A. (1986). Drug-induced pulmonary disease. Part I: Cytotoxic drugs. American Review of Respiratory Disease 133, 321-340.
6. Corcoran B.M., Cobb M., Martin M.W., Dukes-McEwan J., French A., Fuentes V.L., Boswood A., Rhind S. (1999). Chronic pulmonary disease in West Highland white terriers. The Veterinary Record 144, 611-616.
7. Cordonnier C., Vernant J.P., Mitai P., Lange F., Bernaudin J.F., Rochant H. (1983). Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer 51, 1814-1818.
8. Dent R.G. (1982). Fatal pulmonary toxic effects of lomustine. Thorax 37, 627-629.
9. Dweik RA., Ahmad M. (1998). Drug-induced pulmonary disease. In: Baum G.L., Celli J.D.C., Karlinsky J.B. (Editors). Textbook of Pulmonary Diseases. Lippincott-Raven Publishers, Philadelphia, USA, p. 477-490.
10. Evans S.E., Limper A.H. (2006). Acute toxicities of therapy: pulmonary complications. In: Chang A.E., Hayes D.F., Pass H.I., Stone R.M., Ganz P.A., Kinsella T.J., Schiller J.H., Strecher V.J. (Editors). Oncology, An Evidence-Based Approach. Springer New York, p. 1410-1419.
11. Fan T.M., Kitchell B.E. (2000). Pharm profile: lomustine. Compendium on Continuing Education for the Practicing Veterinarian 22, 934-936.
12. Foucher P., Camus P. (2001). The drug-induced lung diseases. Pneumotox online. http://www.pneumotox.com/
13. Hundley R.F., Lukens J.N. (1979). Nitrosourea-associated pulmonary fibrosis. Cancer Treatment Reports 63, 2128-2130.
14. Klein D.S., Wilds P.R. (1983). Pulmonary Toxicity of antineoplastic agents: anaesthetic and postoperative implications. Canadian Anaesthetic Society Journal 30, 399-405.
15. Kristal O., Rassnick K.M., Gliatto J.M., Northrup N.C., Chretin J.D., Morrison-Collister K., Cotter S.M., Moore A.S. (2004). Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine 18, 75-80.
16. Kurup R.K., Kurup P.A. (2003). Hypothalamic digoxin, hemispheric chemical dominance, and interstitial lung disease. International Journal of Neuroscience 113, 1427-1443.
17. Lee W., Moore R.P., Wampler G.L. (1978). Interstitial pulmonary fibrosis as a complication of prolonged methylCCNU therapy. Cancer Treatment Reports 62, 1355-1358.
18. Lees G.E., Brown S.A., Elliott J., Grauer C.F., Vaden S.L. (2005). Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (Small Animal). Journal of Veterinary Internal Medicine 19, 377-385.
19. Lens M.B., Eisen T.G. (2003). Systemic chemotherapy in the treatment of malignant melanoma. Expert Opinion on Pharmacotherapy 4, 2205-2211.
20. Lobetti R.G., Milner R., Lane E. (2001). Chronic idiopathic pulmonary fibrosis in five dogs. Journal of the American Animal Hospital Association 37, 119-127.
21. Lucas S.R.R., Peirera Coehlo B.M., Marquezi M.L., Franchini M.L., Miyashiro S.I., de Benedetto Pozzi D.H. (2004). Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma. Journal of the American Animal Hospital Association 40, 292-299.
22. Marquette C.H., Lahlou C., Farré I., Facon T., Wallaert B., Tonnel A.B. (1992). Fibrose pulmonaire au CCNU (Lomustine). Revue des Maladies Respiratoires 9, R156.
23. Massin F., Coudert B., Foucher P., Lombard J.N., Reybet-Degat O., Jeannin L., Camus P. (1992). Nitrosourea-induced lung diseases. Revue des Maladies Respiratoires 9, 575-582.
24. Merker P.C., Wodinsky I., Geran R.I. (1975). Review of selected experimental brain tumor models used in chemotherapy experiments. Cancer Chemotherapy Report 59, 729-736.
25. Mertens A.C., Yasui Y., Liu Y., Stovall M., Hutchinson R., Ginsberg J., Sklar C., Robison L.L. (2002). Pulmonary complications in survivors of childhood and adolescent cancer. A report from the childhood cancer survivor study. Cancer 95, 2431-2441.
26. Musolino A., Perrone M.A., Michiara M., Delnevo D., Franciosi V., Di Blasio B., Ceci G., Camisa R., Ardizzoni A., Cocconi G. (2005). Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 103, 2109-2117.
27. Norris AJ., Naydan D.K., Wilson D.W. (2005). Interstitial lung disease in West Highland White Terriers. Veterinary Pathology 42, 35-41.
28. O'Driscoll R. (2000). Nitrosourea (carmustine)-induced pulmonary injury. UpToDate in Pulmonary and Critical Care Medicine [on CD-ROM]. American Thoracic Society, v.8.1.
29. Ozkan M., Dweik R.A., Ahmad M. (2001). Drug-induced lung disease. Cleveland Clinic Journal of Medicine 68, 782-795.
30. Parney I.F., Chang S.M. (2003). Current chemotherapy for glioblastoma. Cancer Journal 9, 149-156.
31. Phillips G.L., Reece D.E. (1986). Clinical studies of autologous bone marrow transplantation in Hodgkin's disease. Clinical Haematology 15, 151-166.
32. Rassnick K.M., Moore A.S., Williams L.E., London C.A., Kintzer P.P., Engler S.J., Cotter S.M. (1999). Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 13, 601-605.
33. Risbon R.E., de Lorimier L.P., Skorupski K., Burgess K.E., Bergman PJ., Carreras J., Hahn K., Leblanc A., Turek M., Impellizeri J., Fred R., Wojcieszyn J. W., Drobatz K., Clifford C.A. (2006). Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004). Journal of Veterinary Internal Medicine 20, 1389-1397.
34. Saba C.F., Thamm D.H., Vail D.M. (2007). Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. Journal of Veterinary Internal Medicine 21, 127-132.
35. Sauerbrey M.L., Mullins M.N., Bannink E.O., Van Dorp T.E.R., Kaneene J.B., Obradovich J.E. (2007). Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Journal of the American Veterinary Medical Association 230, 1866-1869.
36. Schabel F.M. (1976). Nitrosoureas: a review of experimental antitumor activity. Cancer Treatment Reports 60, 665-698.
37. Schacht R.G., Feiner H.D., Gallo G.R., Lieberman A., Baldwin D.S. (1981). Nephrotoxicity of nitrosoureas. Cancer 48, 1328-1334.
38. Skorupski K.A., Clifford C.A., Paoloni M.C., Lara-Garcia A., Barber L., Kent M.S., LeBlanc A.K., Sabhlok A., Mauldin E.A., Shofer F.S., Couto C.G., Sorenmo K.U. (2007). CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine 27, 121-126.
39. Smith A.C. (1989). The pulmonary toxicity of nitrosoureas. Pharmacology and Therapeutics 41, 443-460.
40. Stone M.D., Richardson M.G. (1987). Pulmonary toxicity of lomustine. Cancer Treatment Reports 71, 786-787.
41. Stonich T.L., Bressler L. (1998). The Pulmonary Toxicity of Antineoplastic Agents. PMPR 652 course pharmacotherapeutics II. College of Pharmacy, University of Illinois at Chicago, http://www.uic.edu/classes/pmpr/ pmpr652/Final/bressler/pultoxicity.html
42. Stuart MJ., Chao N.S., Homing S.J., Wong R.M., Negrin R.S., Johnston LJ., Shizuru JA., Long G.D., Blume K.G., Stockerl-Goldstein K.E. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biology of Blood and Marrow Transplantation 7, 552-560.
43. Tucci E., Verdiani P., Di Carlo S., Sforza V. (1986). Lomustine (CCNU)-induced pulmonary fibrosis. Tumori 72, 95-98.
44. Twohig K.J., Matthay R. A. (1990). Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine 11, 31-54.
45. Van Meervenne S.A.E., de Vos J.P., Van Ham L.M.L. (2007). Therapy of brain tumors in dogs and cats. Vlaams Diergeneeskundig Tijdschrift 76, 165-176.
46. Vats T.S., Trueworthy R.C., Langston C.M. (1982). Pulmonary fibrosis associated with lomustine (CCNU): a case report. Cancer Treatment Reports 66, 1881-1882.
47. Wakui A. (1982). Cancer chemotherapy with special reference to pharmacokinetics of nitrosoureas. Gan To Kagaku Ryoho / Cancer & Chemotherapy 9, 1327-1338.
48. Webb J.A., Armstrong J. (2002). Chronic idiopathic pulmonary fibrosis in a West Highland white terrier. Canadian Veterinarian Journal 43, 703-705.
49. Weiss R.B., Muggia F.M. (1980). Cytotoxic drug-induced pulmonary disease: update 1980. American Journal of Medicine 68, 259-266.
50. Weiss R.B., Poster D.S., Penta J.S. (1981). The nitrosoureas and pulmonary toxicity. Cancer Treatment Reviews 8, 111-1125.
51. Williams L.E., Rassnick K.M., Power H.T., Lana S.E., Morrison-Collister K.E., Hansen K., Johnson J.L. (2006). CCNU in the treatment of canine epitheliotropic lymphoma. Journal of Veterinary Internal Medicine 20, 136-143.